Patents by Inventor Sumitra Ashokkumar PILLAI
Sumitra Ashokkumar PILLAI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230285368Abstract: Liquid pharmaceutical compositions of apixaban or pharmaceutically acceptable salts thereof are described. More specifically, stable oral liquid pharmaceutical compositions of apixaban for oral administration are provided, wherein the composition is stable for extended periods of time. More specifically, stable liquid pharmaceutical compositions of apixaban at concentrations of 0.4 mg/mL or more are provided. Stable oral liquid compositions of apixaban, methods for their administration, processes for their production, and use of these compositions for treatment of diseases treatable by apixaban are disclosed.Type: ApplicationFiled: March 6, 2023Publication date: September 14, 2023Applicant: Slayback Pharma LLCInventors: Sushant Omprakash Dube, Girish G. Kore, Naga Venkata Durga Prasad Ketha, Sumitra Ashokkumar Pillai, Praveen Kumar Subbappa
-
Publication number: 20230285341Abstract: The present invention relates to stable liquid pharmaceutical compositions of baclofen or a pharmaceutically acceptable salt thereof. More specifically, stable oral suspensions of baclofen at concentrations of equal to or more than 2 mg/mL or more are provided. Preferably, the liquid pharmaceutical compositions of baclofen are suitable for oral administration and are stable at wider pH ranges over a variety of storage conditions, including long-term storage for extended periods of time. Methods of treating various disorders using the inventive pharmaceutical compositions are also provided. The invention further relates to various methods for preparing stable suspension of baclofen.Type: ApplicationFiled: April 4, 2023Publication date: September 14, 2023Applicant: SLAYBACK PHARMA LLCInventors: Sushant Omprakash Dube, Purushottam Sakhahari Pattewar, Pankaj Kisan Chatki, Sumitra Ashokkumar Pillai
-
Publication number: 20230270736Abstract: Pharmaceutical compositions are provided, which comprise cabozantinib or pharmaceutically acceptable salts thereof, and at least one pharmaceutically acceptable excipient, wherein the inventive compositions exhibit enhanced bioavailability compared to the currently marketed or commercially available formulations. The present invention also provides manufacturing processes thereof and use of the said inventive compositions for the prevention, treatment or prophylaxis of disorders in human patients in need thereof. The present invention relates to oral pharmaceutical compositions of cabozantinib, methods for their administration, processes for their production, and use of these compositions for treatment of diseases treatable by cabozantinib.Type: ApplicationFiled: May 5, 2023Publication date: August 31, 2023Applicant: SLAYBACK PHARMA LLCInventors: Sushant Omprakash DUBE, Suprit Dilip SAOJI, Pankaj Kisan CHATKI, Sumitra Ashokkumar PILLAI, Girish G. KORE
-
Patent number: 11707450Abstract: Stable, injectable pharmaceutical compositions are provided, which are useful as ready-to-dilute (RTD) or ready-to-use (RTU) liquid injectable compositions comprising bendamustine or a pharmaceutically acceptable salt thereof, which are suitable for intravenous administration. Preferably, solution formulations comprise (a) bendamustine or its pharmaceutically acceptable salts, solvates, or hydrates thereof, (b) at least one pharmaceutically acceptable non-aqueous solvent; (c) optionally, at least one pharmaceutically acceptable excipient, and (d) optionally, a pH adjuster, where the pharmaceutical composition is antioxidant-free, and formulated as a ready-to-dilute or ready-to-use liquid composition suitable for parenteral administration. The invention further relates to methods for manufacturing stable, antioxidant-free injectable solutions of bendamustine.Type: GrantFiled: July 29, 2022Date of Patent: July 25, 2023Assignee: SLAYBACK PHARMA LLCInventors: Harish Govindaraja Setty Chinnari, Somashekhar Battini, Sumitra Ashokkumar Pillai, Lourdu Chinnu Thippabattuni, Satheesh Balasubramanian
-
Patent number: 11696906Abstract: The present invention relates to stable liquid pharmaceutical compositions of baclofen or a pharmaceutically acceptable salt thereof. More specifically, stable oral suspensions of baclofen at concentrations of equal to or more than 2 mg/mL or more are provided. Preferably, the liquid pharmaceutical compositions of baclofen are suitable for oral administration and are stable at wider pH ranges over a variety of storage conditions, including long-term storage for extended periods of time. Methods of treating various disorders using the inventive pharmaceutical compositions are also provided. The invention further relates to various methods for preparing stable suspension of baclofen.Type: GrantFiled: December 22, 2022Date of Patent: July 11, 2023Assignee: SLAYBACK PHARMA LLCInventors: Sushant Omprakash Dube, Purushottam Sakhahari Pattewar, Pankaj Kisan Chatki, Sumitra Ashokkumar Pillai
-
Publication number: 20230190737Abstract: The present invention relates to stable liquid compositions suitable for parenteral administration in the form of a solution comprising: (a) netupitant and optionally palonosetron; (b) at least one pharmaceutically acceptable stabilizer; (c) at least one pharmaceutically acceptable solubilizer; and (d) at least one pharmaceutically acceptable vehicle, wherein netupitant is present at a concentration of about 0.5 mg/mL to about 20 mg/mL and the solution has a pH of about 2 to about 6. The compositions are suitable for subcutaneous, intravenous, or intramuscular administration. The invention further relates to methods for manufacturing the compositions and methods of using such compositions for prevention, treatment or management of nausea and vomiting.Type: ApplicationFiled: December 20, 2022Publication date: June 22, 2023Applicant: Slayback Pharma LLCInventors: Ashish Anilrao Dubewar, Rahul Dhulaji Bhise, Mahadeo Vasant Mahadik, Shanker Mamidi, Mayur Anshiram Adhav, Raghavender Rao Kategher, Nagaraj Gangam, Sumitra Ashokkumar Pillai, Praveen Kumar Subbappa
-
Patent number: 11679105Abstract: Pharmaceutical compositions are provided, which comprise cabozantinib or pharmaceutically acceptable salts thereof, and at least one pharmaceutically acceptable excipient, wherein the inventive compositions exhibit enhanced bioavailability compared to the currently marketed or commercially available formulations. The present invention also provides manufacturing processes thereof and use of the said inventive compositions for the prevention, treatment or prophylaxis of disorders in human patients in need thereof. The present invention relates to oral pharmaceutical compositions of cabozantinib, methods for their administration, processes for their production, and use of these compositions for treatment of diseases treatable by cabozantinib.Type: GrantFiled: February 10, 2023Date of Patent: June 20, 2023Assignee: SLAYBACK PHARMA LLCInventors: Sushant Omprakash Dube, Suprit Dilip Saoji, Pankaj Kisan Chatki, Sumitra Ashokkumar Pillai, Girish G. Kore
-
Publication number: 20230181561Abstract: Pharmaceutical compositions are provided, which comprise cabozantinib or pharmaceutically acceptable salts thereof, and at least one pharmaceutically acceptable excipient, wherein the inventive compositions exhibit enhanced bioavailability compared to the currently marketed or commercially available formulations. The present invention also provides manufacturing processes thereof and use of the said inventive compositions for the prevention, treatment or prophylaxis of disorders in human patients in need thereof. The present invention relates to oral pharmaceutical compositions of cabozantinib, methods for their administration, processes for their production, and use of these compositions for treatment of diseases treatable by cabozantinib.Type: ApplicationFiled: February 10, 2023Publication date: June 15, 2023Applicant: SLAYBACK PHARMA LLCInventors: Sushant Omprakash DUBE, Suprit Dilip SAOJI, Pankaj Kisan CHATKI, Sumitra Ashokkumar PILLAI, Girish G. KORE
-
Publication number: 20230172863Abstract: The present invention relates to modified-release pharmaceutical compositions of ruxolitinib or its pharmaceutically acceptable salts thereof. Preferably, the invention relates to oral modified-release pharmaceutical compositions of ruxolitinib, which enable once-daily administration. The present invention further relates to oral modified-release compositions of ruxolitinib, methods for their administration, processes for their preparation, and use of these compositions for treatment of diseases treatable by ruxolitinib.Type: ApplicationFiled: December 5, 2022Publication date: June 8, 2023Inventors: Paras P. JAIN, Krishna Mohan LAKSHMIPATHULA, Somnath Devidas NAVGIRE, Hanimi Reddy BAPATU, Sandeep Jain, Sumitra Ashokkumar PILLAI, Praveen Kumar SUBBAPPA
-
Publication number: 20230149359Abstract: The present invention relates to liquid pharmaceutical compositions of clonidine or its pharmaceutically acceptable salts thereof. Preferably, the liquid pharmaceutical compositions are suitable for oral administration, and are stable for extended periods of time. More specifically, stable liquid pharmaceutical compositions of clonidine at concentrations of 1 µg/mL or more are provided. The present invention further relates to stable oral liquid compositions of clonidine, methods for their administration, processes for their production, and use of these compositions for treatment of diseases treatable by clonidine.Type: ApplicationFiled: July 15, 2022Publication date: May 18, 2023Inventors: Shailendra MANDGE, Harish GUNDA, Naga Venkata Durga Prasad KETHA, Venkateshwar Reddy KEESARA, Satheesh Balasubramanian, Sumitra Ashokkumar PILLAI
-
Publication number: 20230139109Abstract: The present invention relates to stable liquid pharmaceutical compositions of baclofen or a pharmaceutically acceptable salt thereof. More specifically, stable oral suspensions of baclofen at concentrations of equal to or more than 2 mg/mL or more are provided. Preferably, the liquid pharmaceutical compositions of baclofen are suitable for oral administration and are stable at wider pH ranges over a variety of storage conditions, including long-term storage for extended periods of time. Methods of treating various disorders using the inventive pharmaceutical compositions are also provided. The invention further relates to various methods for preparing stable suspension of baclofen.Type: ApplicationFiled: December 22, 2022Publication date: May 4, 2023Applicant: SLAYBACK PHARMA LLCInventors: Sushant Omprakash Dube, Purushottam Sakhahari Pattewar, Pankaj Kisan Chatki, Sumitra Ashokkumar Pillai
-
Publication number: 20230119069Abstract: The present invention relates to stable liquid oral compositions of cyclophosphamide having extended stability, methods for their administration, processes for their production, and use of these compositions for treatment of diseases treatable by cyclophosphamide. The invention also relates to a kit comprising stable liquid oral compositions of cyclophosphamide.Type: ApplicationFiled: October 7, 2022Publication date: April 20, 2023Inventors: Shailendra MANDGE, Harish GUNDA, Naga Venkata Durga Prasad KETHA, Venkateshwar Reddy KEESARA, . Satheesh Balasubramanian, Sumitra Ashokkumar PILLAI
-
Publication number: 20230091021Abstract: The present invention relates to injectable pharmaceutical compositions comprising therapeutically effective amount of succinylcholine chloride, one or more pharmaceutically acceptable aqueous solvents, and one or more stabilizing agents selected from aliphatic polyols; lower alkyl alcohols; amino acids having at least one additional amino, carboxyl or hydroxyl group; amino alcohols; and aliphatic dicarboxylic acids having at least one hydroxyl or amino group, or ?-? unsaturation. The compositions are stable at room temperature for at least 30 days. Methods of manufacturing the injectable pharmaceutical compositions are also provided. The composition may be provided in a sealed container, e.g., an ampoule, vial and pre-filled syringe, and are suitable for subcutaneous, intravenous or intramuscular administration as an adjunct to general anesthesia, to facilitate tracheal intubation, and/or to provide skeletal muscle relaxation during surgery or mechanical ventilation.Type: ApplicationFiled: August 26, 2022Publication date: March 23, 2023Applicant: Slayback Pharma LLCInventors: Ashish Anilrao Dubewar, Amit Anil Charkha, Sumitra Ashokkumar Pillai, Pradeep Kumar Kare, Kumar Swamy Ummiti, Shanker Mamidi, Mayur Anshtram Adhav
-
Publication number: 20230086729Abstract: The present invention relates to injectable pharmaceutical compositions comprising therapeutically effective amount of succinylcholine chloride, one or more pharmaceutically acceptable aqueous solvents, and one or more stabilizing agents selected from aliphatic polyols; lower alkyl alcohols; amino acids having at least one additional amino, carboxyl or hydroxyl group; amino alcohols; and aliphatic dicarboxylic acids having at least one hydroxyl or amino group, or ?-? unsaturation. The compositions are stable at room temperature for at least 30 days. Methods of manufacturing the injectable pharmaceutical compositions are also provided. The composition may be provided in a sealed container, e.g., an ampoule, vial and pre-filled syringe, and are suitable for subcutaneous, intravenous or intramuscular administration as an adjunct to general anesthesia, to facilitate tracheal intubation, and/or to provide skeletal muscle relaxation during surgery or mechanical ventilation.Type: ApplicationFiled: August 25, 2022Publication date: March 23, 2023Applicant: Slayback Pharma LLCInventors: Ashish Anilrao Dubewar, Amit Anil Charkha, Sumitra Ashokkumar Pillai, Pradeep Kumar Kare, Kumar Swamy Ummiti, Shanker Mamidi, Mayur Anshtram Adhav
-
Publication number: 20230085008Abstract: Pharmaceutical compositions and stable nano-suspensions comprising mifepristone and at least one pharmaceutically acceptable excipient, which exhibit enhanced bioavailability compared to the currently marketed or commercially available formulations. Manufacturing process and methods of use are also provided. The pharmaceutical compositions are used for prevention, treatment or prophylaxis of disorders in human patients in need thereof. Oral pharmaceutical compositions of mifepristone, methods for their administration, processes for thei r production, and use of these compositions are described for the treatment of diseases for which mifepristone is indicated.Type: ApplicationFiled: June 17, 2022Publication date: March 16, 2023Applicant: SLAYBACK PHARMA LLCInventors: Paras P. JAIN, Somnath Devidas NAVGIRE, Sumitra Ashokkumar PILLAI
-
Patent number: 11590122Abstract: Pharmaceutical compositions are provided, which comprise cabozantinib or pharmaceutically acceptable salts thereof, and at least one pharmaceutically acceptable excipient, wherein the inventive compositions exhibit enhanced bioavailability compared to the currently marketed or commercially available formulations. The present invention also provides manufacturing processes thereof and use of the said inventive compositions for the prevention, treatment or prophylaxis of disorders in human patients in need thereof. The present invention relates to oral pharmaceutical compositions of cabozantinib, methods for their administration, processes for their production, and use of these compositions for treatment of diseases treatable by cabozantinib.Type: GrantFiled: February 16, 2022Date of Patent: February 28, 2023Assignee: SLAYBACK PHARMA LLCInventors: Sushant Omprakash Dube, Suprit Dilip Saoji, Pankaj Kisan Chatki, Sumitra Ashokkumar Pillai, Girish G. Kore
-
Patent number: 11564898Abstract: The present invention relates to stable liquid pharmaceutical compositions of baclofen or a pharmaceutically acceptable salt thereof. More specifically, stable oral suspensions of baclofen at concentrations of equal to or more than 2 mg/mL or more are provided. Preferably, the liquid pharmaceutical compositions of baclofen are suitable for oral administration and are stable at wider pH ranges over a variety of storage conditions, including long-term storage for extended periods of time. Methods of treating various disorders using the inventive pharmaceutical compositions are also provided. The invention further relates to various methods for preparing stable suspension of baclofen.Type: GrantFiled: September 20, 2022Date of Patent: January 31, 2023Assignee: SLAYBACK PHARMA LLCInventors: Sushant Omprakash Dube, Purushottam Sakhahari Pattewar, Pankaj Kisan Chatki, Sumitra Ashokkumar Pillai
-
Publication number: 20230028957Abstract: The present invention relates to stable liquid pharmaceutical compositions of baclofen or a pharmaceutically acceptable salt thereof. More specifically, stable oral suspensions of baclofen at concentrations of equal to or more than 2 mg/mL or more are provided. Preferably, the liquid pharmaceutical compositions of baclofen are suitable for oral administration and are stable at wider pH ranges over a variety of storage conditions, including long-term storage for extended periods of time. Methods of treating various disorders using the inventive pharmaceutical compositions are also provided. The invention further relates to various methods for preparing stable suspension of baclofen.Type: ApplicationFiled: September 20, 2022Publication date: January 26, 2023Applicant: SLAYBACK PHARMA LLCInventors: Sushant Omprakash Dube, Purushottam Sakhahari Pattewar, Pankaj Kisan Chatki, Sumitra Ashokkumar Pillai
-
Publication number: 20220387418Abstract: Pharmaceutical compositions are provided, which comprise cabozantinib or pharmaceutically acceptable salts thereof, and at least one pharmaceutically acceptable excipient, wherein the inventive compositions exhibit enhanced bioavailability compared to the currently marketed or commercially available formulations. The present invention also provides manufacturing processes thereof and use of the said inventive compositions for the prevention, treatment or prophylaxis of disorders in human patients in need thereof. The present invention relates to oral pharmaceutical compositions of cabozantinib, methods for their administration, processes for their production, and use of these compositions for treatment of diseases treatable by cabozantinib.Type: ApplicationFiled: August 10, 2022Publication date: December 8, 2022Applicant: SLAYBACK PHARMA LLCInventors: Sushant Omprakash DUBE, Suprit Dilip SAOJI, Pankaj Kisan CHATKI, Sumitra Ashokkumar PILLAI, Girish G. KORE
-
Publication number: 20220362235Abstract: Pharmaceutical compositions are provided, which comprise cabozantinib or pharmaceutically acceptable salts thereof, and at least one pharmaceutically acceptable excipient, wherein the inventive compositions exhibit enhanced bioavailability compared to the currently marketed or commercially available formulations. The present invention also provides manufacturing processes thereof and use of the said inventive compositions for the prevention, treatment or prophylaxis of disorders in human patients in need thereof. The present invention relates to oral pharmaceutical compositions of cabozantinib, methods for their administration, processes for their production, and use of these compositions for treatment of diseases treatable by cabozantinib.Type: ApplicationFiled: July 18, 2022Publication date: November 17, 2022Applicant: SLAYBACK PHARMA LLCInventors: Sushant Omprakash DUBE, Suprit Dilip SAOJI, Pankaj Kisan CHATKI, Sumitra Ashokkumar PILLAI, Girish G. KORE